Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis - Related Studies

Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

This study is ongoing, but not recruiting participants.

Study NCT00002849. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Amyloidosis
		Multiple Myeloma
		Neoplasms, Plasma Cell

2	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Metabolic Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

3	Interventions listed in this trial
		dexamethasone
		recombinant interferon alfa

4	Additional drug interventions recognized in this trial
		Dexamethasone acetate
		Interferon Alfa-2a
		Interferon Alfa-2b
		Interferon Type I, Recombinant
		Interferon-alpha
		Interferons

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Antiemetics
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Antiviral Agents
		Autonomic Agents
		Central Nervous System Agents
		Gastrointestinal Agents
		Glucocorticoids
		Growth Inhibitors
		Growth Substances
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Southwest Oncology Group
		National Cancer Institute (NCI)
		Cancer and Leukemia Group B